Recently, Pan et al. revealed that PKM2 inhibitors (shikonin or compound 3K) targeting the glycolysis/H4K12la/Pkm2 loop reduced the extent of reactive microgliosis, partially reversed the amoeboid morphology of microglia, and significantly improved spatial learning and memory in AD models, suggesting a promising strategy for mitigating neuroinflammation in AD and other neurodegenerative diseases (Pan et al., 2022). Here, PKM is linked to Alzheimer disease.